Navigation Links
3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
Date:9/10/2012

SHENYANG, China, Sept. 10, 2012 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the 2012 annual general meeting of shareholders will be held on October 10,  2012 at 10:00 a.m., Beijing time, at our executive office, 15/A-D, Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District, Shenyang 110016, People's Republic of China.

Holders of record of ordinary shares of the Company at the close of business on August 31, 2012 ("Record Date") are entitled to notice of and to vote at the annual general meeting or any adjournment or postponement thereof. Holders of the Company's American depositary shares ("ADSs") who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company's ADS program, JPMorgan Chase Bank, N.A. 

3SBio has filed its annual report on Form 20-F containing the audited financial statements for the fiscal year ended December 31, 20011 with the U.S. Securities and Exchange Commission (the "SEC"), available on SEC's website at http://www.sec.gov. 3SBio's annual report on Form 20-F can also be accessed on the Investors section of the Company's website at http://www.3SBio.com. The materials related to the 2012 annual general meeting, including the notice of meeting, the proxy statement, and the ADR voting card may also be accessed and downloaded at the Investors section of the Company website under the "AGM" heading.  Additionally, shareholders may request a hard copy of the above documents free of charge by contacting ir@3SBio.com.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX." Please see www.3SBio.com for more information.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


 


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Apexigen Announces the Filing of an IND by its Partner, 3SBio
2. 3SBio Inc. Announces Changes to Its Board of Directors
3. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
4. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
5. 3SBio Inc. To Present at the DB Access Asia Conference 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. GP Strategies to Present at the BMO Capital Markets 12th Annual Back to School Education Conference
10. Omnicell To Present At Think Equitys 9th Annual Growth Conference: G9
11. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... 2016   BIOTRONIK , a leader in ... and Drug Administration (FDA) approval of Iperia ProMRI ... failure patients with access to diagnostic magnetic resonance ... monitoring with daily automatic transmission and closed loop ... response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of ... and corporate training, and the National Military Family Association, a nonprofit that works ... the second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship ...
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food ... requiring e-cigarette manufacturers to submit their products through an arduous federal approval process. ... products that entered the market since February 15, 2007. That would essentially ban ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
(Date:5/5/2016)... Bremerton, WA (PRWEB) , ... May 05, 2016 , ... ... program serving the families of Bremerton, Port Orchard and communities west of Seattle. The ... Lowery, a 12 year local girl who died suddenly due to complications from the ...
Breaking Medicine News(10 mins):